CBX7, a Potential Prognostic Biomarker in Lung Adenocarcinoma

Yang, Yuqiao; Hu, Zaoxiu; Sun, Hongwen; Yu, Qinghe; Yang, Linzhu; Yin, Fei; Sun, Yongmen; Pu, Lisha; Zhu, Xingming; Sheng, Li; Chen, Xiaobo; Zhao, Yunping

doi:10.2147/ott.s325203

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among known immunotherapy predictive biomarkers such as PD-L1, PD-1, CTLA-4, and TMB, as well as potential biomarkers predicted by the current studies, such as AUNIP, NPM1, EXO1, CBX7, and SFTPA1, increased AUNIP, NPM1, and EXO1 expression predicted worse OS in LUAD patients ( 68 - 70 ). In contrast, higher SFTPA1 and CBX7 expression predicted better outcome in LUAD patients ( 71 , 72 ). Comparing them with the IRGPI risk score, we found that the IRGPI score significantly correlated with these biomarkers, except for PD-L1.…”

Section: Discussionmentioning

confidence: 90%

Development and validation of an immune-related gene prognostic index for lung adenocarcinoma

Liu,

Lei,

Shen

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background Lung cancer is the most common malignant tumor in the world, and its prognosis is still not optimistic. The aim of this study was to establish an immune-related gene (IRG) prognostic index (IRGPI) for lung adenocarcinoma (LUAD) based on IRGs, and to explore the prognosis, molecular and immune features, and response to immune checkpoint inhibitor (ICI) therapy in IRGPI-classified different subgroups of LUAD. Methods Based on the LUAD transcriptome RNA-sequencing data in TCGA database, the differentially expressed genes (DEGs) were selected. Subsequently, DEGs were intersected with IRGs to obtain differentially expressed immune-related genes (DEIRGs). Weighted gene co-expression network analysis (WGCNA) identified hub genes in DEIRGs. Finally, univariate and multivariate Cox regression analyses were used to build an IRGPI model. Subsequently, TCGA patients were divided into high- and low-risk groups, and the survival of patients in different groups was further analyzed. Besides, we validated the molecular and immune characteristics, relationship with immune checkpoints, angiogenesis-related genes, and immune subtypes distribution in different subgroups. Meanwhile, we further validated the response to ICI therapy in different subgroups. Results The IRGPI was constructed based on 13 DEIRGs. Compared with the low-risk group, overall survival (OS) was lower in the high-risk group, and the high-risk score was independently associated with poorer OS. Besides, the high-risk score was associated with cell cycle pathway, high mutation rate of TP53 and KRAS , high infiltration of M0 macrophages, and immunosuppressive state, and these patients had poorer prognosis but the TIDE score of the high-risk group was lower than that of the other group, which means that the high-risk group could benefit more from ICI treatment. In contrast, the low-risk score was related to low mutation rate of TP53 and KRAS , high infiltration of plasma cells, and immunoactive state, and these patients had better prognosis but the low-risk group less benefit from ICI treatment based on the results of TIDE score. Conclusions IRGPI is a prospective biomarker based on IRGs that can distinguish high- and low-risk groups to predict patient prognosis, help characterize the tumor immune microenvironment, and evaluate the benefit of ICI therapy in LUAD.

show abstract

Section: Discussionmentioning

confidence: 90%

Development and validation of an immune-related gene prognostic index for lung adenocarcinoma

Liu,

Lei,

Shen

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…Chromobox 7 (CBX7), is a member of the chromobox family. It has been reported to involve in oncogenesis, which may be deregulated in gliomas ( Bao et al, 2017 ), breast cancer ( Kim et al, 2015 ), cervical carcinoma ( Maimaitirexiati et al, 2021 ), lung cancer ( Yang et al, 2021 ), etc. Studies have shown that CBX7 can participate in maintaining the growth of a variety of normal cells and immortalizing mouse fibroblasts ( Jung et al, 2019 ), but the controversy about its role persists.…”

Section: Discussionmentioning

confidence: 99%

A novel risk score model based on fourteen chromatin regulators-based genes for predicting overall survival of patients with lower-grade gliomas

Zhang

Tian

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Low grade gliomas(LGGs) present vexatious management issues for neurosurgeons. Chromatin regulators (CRs) are emerging as a focus of tumor research due to their pivotal role in tumorigenesis and progression. Hence, the goal of the current work was to unveil the function and value of CRs in patients with LGGs.Methods: RNA-Sequencing and corresponding clinical data were extracted from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) database. A single-cell RNA-seq dataset was sourced from the Gene Expression Omnibus (GEO) database. Altogether 870 CRs were retrieved from the published articles in top academic journals. The least absolute shrinkage and selection operator (LASSO) algorithm and Cox regression analysis were applied to construct the prognostic risk model. Patients were then assigned into high- and low-risk groups based on the median risk score. The Kaplan–Meier (K-M) survival curve and receiver operating characteristic curve (ROC) were performed to assess the prognostic value. Sequentially, functional enrichment, tumor immune microenvironment, tumor mutation burden, drug prediction, single cell analysis and so on were analyzed to further explore the value of CR-based signature. Finally, the expression of signature genes were validated by immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR).Results: We successfully constructed and validated a 14 CRs-based model for predicting the prognosis of patients with LGGs. Moreover, we also found 14 CRs-based model was an independent prognostic factor. Functional analysis revealed that the differentially expressed genes were mainly enriched in tumor and immune related pathways. Subsequently, our research uncovered that LGGs patients with higher risk scores exhibited a higher TMB and were less likely to be responsive to immunotherapy. Meanwhile, the results of drug analysis offered several potential drug candidates. Furthermore, tSNE plots highlighting the magnitude of expression of the genes of interest in the cells from the scRNA-seq assay. Ultimately, transcription expression of six representative signature genes at the mRNA level was consistent with their protein expression changes.Conclusion: Our findings provided a reliable biomarker for predicting the prognosis, which is expected to offer new insight into LGGs management and would hopefully become a promising target for future research.

show abstract

“…CBX6 may be either a poor prognostic factor or a favorable prognostic factor, depending on the type of cancer (67,77,94,(96)(97)(98)(99)103,110,117,122). CBX7 acts as a tumor suppressor in glioma (68), BC (15,77), LUAD (83,84,125), HCC (114,119), PAAD (99,109), ccRCC (110), CCA (112), sarcoma (106) and SKCM (113). When the expression of CBX7 is low, the OS of patients is shorter, but its relationship to survival in EC (86)(87)(88) and GC (94-98) is controversial.…”

Section: Othersmentioning

confidence: 99%

Chromobox proteins in cancer: Multifaceted functions and strategies for modulation (Review)

et al. 2023

View full text Add to dashboard Cite

Chromobox (CBX) proteins are important epigenetic regulatory proteins and are widely involved in biological processes, such as embryonic development, the maintenance of stem cell characteristics and the regulation of cell proliferation and apoptosis. Disorder and dysfunction of CBXs in cancer usually lead to the blockade or ectoptic activation of developmental pathways, promoting the occurrence, development and progression of cancer. In the present review, the characteristics and functions of CBXs were first introduced. Subsequently, the expression of CBXs in cancers and the relationship between CBXs and clinical characteristics (mainly cancer grade, stage, metastasis and relapse) and prognosis were discussed. Finally, it was described how CBXs regulate cell proliferation and self-renewal, apoptosis and the acquisition of malignant phenotypes, such as invasion, migration and chemoresistance, through mechanisms involving epigenetic modification, nuclear translocation, noncoding RNA interactions, transcriptional regulation, posttranslational modifications, protein-protein interactions, signal transduction and metabolic reprogramming. The study also focused on cancer therapies targeting CBXs. The present review provides new insight and a comprehensive basis for follow-up research on CBXs and cancer. Contents1. Introduction 2. Constituent members of CBXs 3. Characteristics and functions of PcG family CBXs 4. Characteristics and functions of HP1 family CBXs 5. Expression of CBXs in cancers and the relationship between CBXs and clinical characteristics and prognosis 6. CBXs regulate biological tumor processes through epigenetic modification, nuclear translocation, ncRNA interactions, transcriptional regulation, PTMs, proteinprotein interactions, signal transduction and metabolic reprogramming 7. Cancer therapies targeting CBXs 8. Conclusion and prospects

show abstract

CBX7, a Potential Prognostic Biomarker in Lung Adenocarcinoma

Cited by 4 publications

References 27 publications

Development and validation of an immune-related gene prognostic index for lung adenocarcinoma

Development and validation of an immune-related gene prognostic index for lung adenocarcinoma

A novel risk score model based on fourteen chromatin regulators-based genes for predicting overall survival of patients with lower-grade gliomas

Chromobox proteins in cancer: Multifaceted functions and strategies for modulation (Review)

Contact Info

Product

Resources

About